Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
I. Psallidas, S. Karabela, C. Moschos, A. Kollintza, P. Theodoropoulou, C. Roussos, I. Kalomenidis, G. T. Stathopoulos (Athens, Greece). The proteasome inhibitor bortezomib is effective against experimental malignant pleural effusion. Eur Respir J 2008; 32: Suppl. 52, 3000

Member's Comments

No comment yet.

Related content which might interest you: The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Systemic treatment of malignant pleural effusion Source: Annual Congress 2005 - What's new in the pleura Year: 2005 mTOR inhibition blocks tumor growth and pleural fluid accumulation in experimental murine mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 Early pleural fluid control is warranted to prevent reaccumulation of malignant pleural effusion in oncogene-driven lung cancer Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019 The therapeutic efficacy of troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Pleurodesis in the treatment of malignant pleural effusion Source: Eur Respir J 2004; 24: Suppl. 48, 628s Year: 2004 Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions Source: Eur Respir J 2004; 24: 263-266 Year: 2004 Management of malignant pleural effusion in recurrent SCLC by intrapleural gene therapy Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Videothoracoscopy in the treatment of malignant pleural effusions Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012 Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 Diagnostic implications of telomerase activity in pleural effusions Source: Eur Respir J 2003; 22: 422-426 Year: 2003 Results of treatment of the metastatic pleural effusion Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012 Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 Survival of lung adenocarcinoma patients with malignant pleural effusion Source: Eur Respir J 2013; 41: 1409-1418 Year: 2013 In patients with treatment-sensitive cancers, does systemic anti-cancer therapy increase the chance of malignant pleural effusion control? Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Efficacy of EGFR-TKI for malignant pleural effusion in lung adenocarcinoma patients Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Is the size of pleural effusion important in the study of patients whose first tumor manifestation is a pleural effusion? Source: International Congress 2017 – Pleural and mediastinal malignancies Year: 2017 ADAM10 membrane-bound protease mediates malignant pleural mesothelioma invasiveness Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management Year: 2018